Systemic amyloidosis: Novel therapies and role of biomarkers

Nephrology Dialysis Transplantation

Volumn 32, Issue 5, 2017, Pages 770-780

  Nuvolone, Mario ^a,b   Merlini, Giampaolo ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

cardiac amyloidosis; immunotherapy; novel therapies; protein misfolding; renal amyloidosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID P COMPONENT; BIOLOGICAL MARKER; BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CARFILZOMIB; COLCHICINE; CYCLOPHOSPHAMIDE; DARATUMUMAB; DEXAMETHASONE; DIFLUNISAL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; ELOTUZUMAB; EPIGALLOCATECHIN GALLATE; EPRODISATE; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; IXAZOMIB; LENALIDOMIDE; MELPHALAN; NEOD 001; POMALIDOMIDE; STEROID; TAFAMIDIS; THALIDOMIDE; TROPONIN I; TROPONIN T; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AA AMYLOIDOSIS; AL AMYLOIDOSIS; AMYLOIDOSIS; ATTR AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHRONIC ARTHRITIS; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; GLOMERULUS FILTRATION; HEART AMYLOIDOSIS; HUMAN; NEUROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; METABOLISM; PROGNOSIS;

AMYLOIDOSIS; BIOMARKERS; HUMANS; PROGNOSIS;

EID: 85018747356     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw305     Document Type: Review

References (103)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl JMed 2003; 349: 583-596
2. Merlini G, Seldin DC, GertzMA. Amyloidosis: Pathogenesis and new therapeutic options. J Clin Oncol 2011; 29: 1924-1933
3. Sipe JD, BensonMD, Buxbaum JN et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014; 21: 221-224
4. Schonland SO, Hegenbart U, Bochtler T et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: A systematic investigation of 117 patients. Blood 2012; 119: 488-493
5. Fernandez de Larrea C, Verga L, Morbini P et al. A practical approach to the diagnosis of systemic amyloidoses. Blood 2015; 125: 2239-2244
6. Brambilla F, Lavatelli F, Di Silvestre D et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012; 119: 1844-1847
7. Vrana JA, Gamez JD, Madden BJ et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114: 4957-4959
8. Lavatelli F, Albertini R, Di Fonzo A et al. Biochemical markers in early diagnosis and management of systemic amyloidoses. Clin Chem Lab Med 2014; 52: 1517-1531
9. Kyle RA, Linos A, Beard CMet al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79: 1817-1822
10. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108: 2520-2530
11. Nasr SH, Said SM, Valeri AM et al. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int 2013; 83: 463-470
12. Palladini G, Milani P, Merlini G. Novel strategies for the diagnosis and treatment of cardiac amyloidosis. Expert Rev Cardiovasc Ther 2015; 13: 1195-1211
13. Graziani MS, Merlini G. Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions. Expert Rev Mol Diagn 2014; 14: 55-66
14. Palladini G, Campana C, Klersy C et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440-2445
15. Gertz MA, Comenzo R, Falk RH et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328
16. Kumar S, Dispenzieri A, Lacy MQ et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chainmeasurements. J Clin Oncol 2012; 30: 989-995
17. Palladini G, Dispenzieri A, Gertz MA et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes. J Clin Oncol 2012; 30: 4541-4549
18. Palladini G, Hegenbart U, Milani P et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 2014; 124: 2325-2332
19. Palladini G, Foli A, Milani P et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 2012; 87: 465-471
20. Palladini G, Barassi A, Perlini S et al. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid 2011; 18: 216-221
21. Kristen AV, Rosenberg M, Lindenmaier D et al. Osteopontin: A novel predictor of survival in patients with systemic light-chain amyloidosis. Amyloid 2014; 21: 202-210
22. Dispenzieri A, GertzMA, Saenger A et al. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. Am J Hematol 2015; 90: 524-528
23. Bradwell AR, Carr-Smith HD, Mead GP et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673-680
24. Palladini G, Russo P, Bosoni T et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009; 55: 499-504
25. Dispenzieri A, Lacy MQ, Katzmann JA et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006; 107: 3378-3383
26. Palladini G, Milani P, Foli A et al. The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis. Clin Chem Lab Med 2016; 54: 939-945
27. Barnidge DR, Dispenzieri A, Merlini G et al. Monitoring free light chains in serum using mass spectrometry. Clin Chem Lab Med 2016; 54: 1073-1083
28. Kastritis E, Dimopoulos MA. Recent advances in the management of AL Amyloidosis. Br J Haematol 2016; 172: 170-186
29. Palladini G, Lavatelli F, Russo P et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006; 107: 3854-3858
30. Liao R, Jain M, Teller P et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001; 104: 1594-1597
31. Brenner DA, JainM, Pimentel DR et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004; 94: 1008-1010
32. Shi J, Guan J, Jiang B et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci USA 2010; 107: 4188-4193
33. Diomede L, Rognoni P, Lavatelli F et al. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood 2014; 123: 3543-3552
34. Palladini G, Sachchithanantham S, Milani P et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 2015; 126: 612-615
35. D'Souza A, Dispenzieri A, Wirk B et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study. J Clin Oncol 2015; 33: 3741-3749
36. Casserly LF, Fadia A, Sanchorawala V et al. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosisassociated end-stage renal disease. Kidney Int 2003; 63: 1051-1057
37. Leung N, Kumar SK, Glavey SV et al. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrol Dial Transplant 2015; 0: 1-6
38. Palladini G, Perfetti V, Obici L et al. Association of melphalan and highdose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936-2938
39. Palladini G, Russo P, Nuvolone M et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007; 110: 787-788
40. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: Targeted therapy?. Haematologica 2007; 92: 1302-1307
41. Reece DE, Hegenbart U, Sanchorawala V et al. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood 2014; 124: 2498-2506
42. Sanchorawala V, Brauneis D, Shelton AC et al. Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: Results of a prospective clinical trial. Biol BloodMarrow Transplant 2015; 21: 1445-1451
43. Landau H, Hassoun H, Rosenzweig MA et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013; 27: 823-828
44. Palladini G, Milani P, Foli A et al. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: A matched case- control study on 174 patients. Leukemia 2014; 28: 2311-2316
45. Venner CP, Lane T, Foard D et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012; 119: 4387-4390
46. Mikhael JR, Schuster SR, Jimenez-Zepeda VH et al. Cyclophosphamidebortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119: 4391-4394
47. Jaccard A, Comenzo RL, Hari P et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica 2014; 99: 1479-1485
48. Merlini G, Sanchorawala V, Jeffrey ZA et al. Long-term outcome of a phase 1 study of the investigational oral proteasome inhibitor (PI) ixazomib at the recommended phase 3 dose (RP3D) in patients (Pts) with relapsed or refractory systemic light-chain (AL) amyloidosis (RRAL). Blood 2014; 124: 3450
49. Cohen AD, Scott EC, Liedtke M et al. A phase I dose-escalation study of carfilzomib in patients with previously-treated systemic light-chain (AL) amyloidosis. Blood 2014; 124: 4741
50. Mikhael J. Management of carfilzomib-associated cardiac adverse events. Clin LymphomaMyeloma Leuk 2016; 16: 241-245
51. Dispenzieri A, Lacy MQ, Zeldenrust SR et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007; 109: 465-470
52. Dispenzieri A, Buadi F, Laumann K et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 2012; 119: 5397-5404
53. Dispenzieri A, Dingli D, Kumar SK et al. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immunemodulatory drugs. Am J Hematol 2010; 85: 757-759
54. Sattianayagam PT, Gibbs SD, Pinney JH et al. Solid organ transplantation in AL amyloidosis. Am J Transplant 2010; 10: 2124-2131
55. Leung N, GriffinMD, Dispenzieri A et al. Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant 2005; 5: 1660-1670
56. Lokhorst HM, Plesner T, Laubach JP et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015; 373: 1207-1219
57. Lonial S, Dimopoulos M, Palumbo A et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. NEngl J Med 2015; 373: 621-631
58. Garfall AL, Maus MV, HwangWT et al. Chimeric antigen receptor T cells against CD19 formultiplemyeloma. N Engl JMed 2015; 373: 1040-1047
59. Bianchi G, Richardson PG, Anderson KC. Promising therapies in multiple myeloma. Blood 2015; 126: 300-310
60. Wall JS, Kennel SJ, Williams A et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One 2012; 7: E52686
61. Gertz MA, Landau H, Comenzo RL et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol 2016; 34: 1097-1103
62. Solomon A, Weiss DT, Wall JS. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm 2003; 18: 853-860
63. Ohno S, Yoshimoto M, Honda S et al. The antisense approach in amyloid light chain amyloidosis: Identification of monoclonal Ig and inhibition of its production by antisense oligonucleotides in in vitro and in vivo models. J Immunol 2002; 169: 4039-4045
64. Phipps JE, Kestler DP, Foster JS et al. Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules. Exp Hematol 2010; 38: 1006-1013
65. Hovey BM, Ward JE, Soo Hoo P et al. Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther 2011; 12: 1150-1156
66. Zhou P, Ma X, Iyer L et al. One siRNA pool targeting the lambda constant region stops lambda light-chain production and causes terminal endoplasmic reticulum stress. Blood 2014; 123: 3440-3451
67. Cooley CB, Ryno LM, Plate L et al. Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain. Proc Natl Acad Sci USA 2014; 111: 13046- 13051
68. Brumshtein B, Esswein SR, Salwinski L et al. Inhibition by small-molecule ligands of formation of amyloid fibrils of an immunoglobulin light chain variable domain. Elife 2015; 4: E10935
69. Obici L, Merlini G. AA amyloidosis: Basic knowledge, unmet needs and future treatments. SwissMed Wkly 2012; 142: w13580
70. Westermark GT, Fandrich M, Westermark P. AA amyloidosis: Pathogenesis and targeted therapy. Annu Rev Pathol 2015; 10: 321-344
71. Lachmann HJ, Goodman HJ, Gilbertson JA et al. Natural history and outcome in systemic AA amyloidosis. NEngl J Med 2007; 356: 2361-2371
72. Pinney JH, Lachmann HJ, Sattianayagam PT et al. Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance. Am J Transplant 2013; 13: 433-441
73. Kofman T, Grimbert P, Canoui-Poitrine F et al. Renal transplantation in patients with AA amyloidosis nephropathy: Results from a French multicenter study. Am J Transplant 2011; 11: 2423-2431
74. Keven K, Sengul S, Kutlay S et al. Long-term outcome of renal transplantation in patients with familial Mediterranean fever amyloidosis: A singlecenter experience. Transplant Proc 2004; 36: 2632-2634
75. Kisilevsky R, Lemieux LJ, Fraser PE et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease. NatMed 1995; 1: 143-148
76. Dember LM, Hawkins PN, Hazenberg BP et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007; 356: 2349-2360
77. Rumjon A, Coats T, Javaid MM. Review of eprodisate for the treatment of renal disease in AA amyloidosis. Int J Nephrol Renovasc Dis 2012; 5: 37-43
78. Kluve-Beckerman B, Hardwick J, Du L et al. Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis. Amyloid 2011; 18: 136-146
79. Gertz MA, BensonMD, Dyck PJ et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-2466
80. Rapezzi C, Merlini G, Quarta CC et al. Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types. Circulation 2009; 120: 1203-1212
81. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011; 10: 1086-1097
82. Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol 2012; 7: 1337-1346
83. Ericzon B-G, Wilczek HE, Larsson M et al. Liver transplantation for hereditary transthyretin amyloidosis. Transplantation 2015; 99: 1847-1854
84. Liepnieks JJ, Benson MD. Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid 2007; 14: 277-282
85. Beirao JM, Malheiro J, Lemos C et al. Impact of liver transplantation on the natural history of oculopathy in Portuguese patients with transthyretin (V30M) amyloidosis. Amyloid 2015; 22: 31-35
86. Coelho T, Adams D, Silva A et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. NEngl JMed 2013; 369: 819-829
87. Coelho T, Maia LF, Martins da Silva A et al. Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology 2012; 79: 785-792
88. Coelho T, Maia LF, da Silva AM et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013; 260: 2802-2814
89. Merlini G, Plante-Bordeneuve V, Judge DP et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res 2013; 6: 1011-1020
90. Maurer MS, Grogan DR, Judge DP et al. Tafamidis in transthyretin amyloid cardiomyopathy: Effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail 2015; 8: 519-526
91. Berk JL, Suhr OB, Obici L et al. Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial. JAMA 2013; 310: 2658-2667
92. Sant'Anna R, Gallego P, Robinson LZ et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun 2016; 7: 10787
93. Merlini G, Ascari E, Amboldi N et al. Interaction of the anthracycline 40-iodo-40-deoxydoxorubicin with amyloid fibrils-inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995; 92: 2959-2963
94. Gianni L, Bellotti V, Gianni AM et al. New drug-therapy of amyloidoses -resorption of AL-type deposits with 40-iodo-40-deoxydoxorubicin. Blood 1995; 86: 855-861
95. Cardoso I, Martins D, Ribeiro T et al. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: Studies in FAPmouse models. J TranslMed 2010; 8: 74
96. Wechalekar A, Whelan C, Lachmann H et al. Oral doxycycline improves outcomes of stage III AL amyloidosis-a matched case-control study. Blood 2015; 126: Abstract 732
97. Obici L, Cortese A, Lozza A et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: A phase II study. Amyloid 2012; 19 (Suppl 1): 34-36
98. Ehrnhoefer DE, Bieschke J, Boeddrich A et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 2008; 15: 558-566
99. Hunstein W. Epigallocathechin-3-gallate in AL amyloidosis: A new therapeutic option?. Blood 2007; 110: 2216
100. Mereles D, Buss SJ, Hardt SE et al. Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol 2010; 99: 483-490
101. Richards DB, Cookson LM, Berges AC et al. Therapeutic clearance of amyloid by antibodies to serumamyloid P component. NEngl JMed 2015; 373: 1106-1114
102. Pepys MB, Cookson LM, Barton SV et al. Dose-dependent progressive immunotherapeutic clearance of systemic amyloid deposits by repeated doses of antibody to serum amyloid P component (SAP). Blood 2015; 126: 1836
103. Comenzo RL, Reece D, Palladini G et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012; 26: 2317-2325